<DOC>
	<DOCNO>NCT01806961</DOCNO>
	<brief_summary>Determine recurrence rate actinic keratosis ( AK ) lesions patient complete clinical clearance end previous trial SP848-AK-1101 6 12 month follow-up .</brief_summary>
	<brief_title>Observational Trial Tolerability Efficacy Resiquimod Gel Patients Treated Actinic Keratosis .</brief_title>
	<detailed_description>Efficacy Evaluation : â€¢ Primarily base clinical inspection former 25 cm2 treatment area count AK-lesions . Safety Evaluation : - Evaluation adverse event ( AEs ) serious adverse event ( SAEs ) - Evaluation newly occur dermal adverse event ( AEs ) serious adverse event ( SAEs ) previous treatment area 6 month 12 month follow-up ( local tolerability ) . - Follow-up unresolved adverse serious adverse event occur previous trial SP848-AK-1101 . - Follow-up unresolved abnormal laboratory value occur previous trial SP848-AK-1101 .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Signed informed consent . Participation previous clinical trial SP848AK1101 . Patient complete clinical clearance ( i.e . previously exist AKlesion present ) end trial SP848AK1101 NonResponder withdraw trial prematurely . Evidence unstable uncontrolled clinically significant medical condition determine investigator ( e.g. , cardiovascular , immunological , hematologic , hepatic , neurologic , renal , endocrine , collagenvascular , infectious , gastrointestinal abnormality disease ) . Evidence systemic cancer . Dermatological disease condition former treatment surround area might impair trial assessment ( e.g. , rosacea , atopic dermatitis , eczema ) assess investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>